Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Human chorionic gonadotropin induces decidualization of ectopic human endometrium more effectively than forskolin in an in-vivo endometriosis model.

Koch Y, Wimberger P, Grümmer R.

Exp Biol Med (Maywood). 2018 Jan 1:1535370218782658. doi: 10.1177/1535370218782658. [Epub ahead of print]

PMID:
29886768
2.

Correction to: The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer.

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, Glenn McCluggage W, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR.

Virchows Arch. 2018 Jun;472(6):937-938. doi: 10.1007/s00428-018-2380-7.

PMID:
29789924
3.

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer.

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR.

Radiother Oncol. 2018 Apr 12. pii: S0167-8140(18)30135-X. doi: 10.1016/j.radonc.2018.03.003. [Epub ahead of print]

PMID:
29728273
4.

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer.

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR.

Virchows Arch. 2018 Jun;472(6):919-936. doi: 10.1007/s00428-018-2362-9. Epub 2018 May 4. Erratum in: Virchows Arch. 2018 May 23;:.

PMID:
29725757
5.

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR.

Int J Gynecol Cancer. 2018 May;28(4):641-655. doi: 10.1097/IGC.0000000000001216.

PMID:
29688967
6.

Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.

Runnebaum IB, Reichert D, Ringsdorf U, Kuther M, Hesse T, Sehouli J, Wimberger P.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1185-1195. doi: 10.1007/s00432-018-2637-1. Epub 2018 Apr 6.

7.

Evolution and cell-type specificity of human-specific genes preferentially expressed in progenitors of fetal neocortex.

Florio M, Heide M, Pinson A, Brandl H, Albert M, Winkler S, Wimberger P, Huttner WB, Hiller M.

Elife. 2018 Mar 21;7. pii: e32332. doi: 10.7554/eLife.32332.

8.
9.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the German "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
10.

Changes in classification of genetic variants in BRCA1 and BRCA2.

Kast K, Wimberger P, Arnold N.

Arch Gynecol Obstet. 2018 Feb;297(2):279-280. doi: 10.1007/s00404-017-4631-2. Epub 2018 Jan 4.

PMID:
29302806
11.

Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.

Müller V, Nabieva N, Häberle L, Taran FA, Hartkopf AD, Volz B, Overkamp F, Brandl AL, Kolberg HC, Hadji P, Tesch H, Ettl J, Lux MP, Lüftner D, Belleville E, Fasching PA, Janni W, Beckmann MW, Wimberger P, Hielscher C, Fehm TN, Brucker SY, Wallwiener D, Schneeweiss A, Wallwiener M.

Breast. 2018 Feb;37:154-160. doi: 10.1016/j.breast.2017.08.008. Epub 2017 Dec 10.

PMID:
29237546
12.

Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation.

Schüring AN, Fehm T, Behringer K, Goeckenjan M, Wimberger P, Henes M, Henes J, Fey MF, von Wolff M.

Arch Gynecol Obstet. 2018 Jan;297(1):241-255. doi: 10.1007/s00404-017-4594-3. Epub 2017 Nov 24.

13.

Screening for Type 1 Diabetes Risk in Newborns: The Freder1k Pilot Study in Saxony.

Hommel A, Haupt F, Delivani P, Winkler C, Stopsack M, Wimberger P, Nitzsche K, Heinke S, Naeke A, Ceglarek U, Thiery J, Bergert R, Stadthaus D, Groeger K, Heubner G, Schramm U, Dziambor U, Zirkel A, Kiess W, Mueller I, Lange K, Berner R, Bonifacio E, Ziegler AG; and the Freder1k Study Group.

Horm Metab Res. 2018 Jan;50(1):44-49. doi: 10.1055/s-0043-120921. Epub 2017 Nov 9.

PMID:
29121687
14.

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro.

Schott S, Wimberger P, Klink B, Grützmann K, Puppe J, Wauer US, Klotz DM, Schröck E, Kuhlmann JD.

Oncotarget. 2017 Aug 14;8(44):76935-76948. doi: 10.18632/oncotarget.20260. eCollection 2017 Sep 29.

15.

Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.

Hartkopf AD, Huober J, Volz B, Nabieva N, Taran FA, Schwitulla J, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lux MP, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching PA, Janni W, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A.

Breast. 2018 Feb;37:42-51. doi: 10.1016/j.breast.2017.10.002. Epub 2017 Oct 26.

PMID:
29100043
16.

A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA.

Cancer Res. 2018 Jan 1;78(1):129-142. doi: 10.1158/0008-5472.CAN-16-3507. Epub 2017 Oct 24.

PMID:
29066511
17.

Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?

Klotz DM, Wimberger P.

Arch Gynecol Obstet. 2017 Dec;296(6):1055-1062. doi: 10.1007/s00404-017-4529-z. Epub 2017 Sep 23. Review.

PMID:
28940023
18.

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.

Link T, Kuithan F, Ehninger A, Kuhlmann JD, Kramer M, Werner A, Gatzweiler A, Richter B, Ehninger G, Baretton G, Bachmann M, Wimberger P, Friedrich K.

Oncotarget. 2017 Apr 29;8(33):54592-54603. doi: 10.18632/oncotarget.17523. eCollection 2017 Aug 15.

19.

BRCA1/2 missense mutations and the value of in-silico analyses.

Sadowski CE, Kohlstedt D, Meisel C, Keller K, Becker K, Mackenroth L, Rump A, Schröck E, Wimberger P, Kast K.

Eur J Med Genet. 2017 Nov;60(11):572-577. doi: 10.1016/j.ejmg.2017.08.005. Epub 2017 Aug 12.

PMID:
28807866
20.

Trastuzumab and survival of patients with metastatic breast cancer.

Kast K, Schoffer O, Link T, Forberger A, Petzold A, Niedostatek A, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P.

Arch Gynecol Obstet. 2017 Aug;296(2):303-312. doi: 10.1007/s00404-017-4421-x. Epub 2017 Jun 14.

PMID:
28616827
21.

[Increasing Consumption of Crystal Meth in Saxony and its Risks for Mother and Child - Experiences at a Level I Perinatal Center from a Pediatric Viewpoint].

Dinger J, Näther N, Wimberger P, Zimmermann US, Schmitt J, Reichert J, Rüdiger M.

Z Geburtshilfe Neonatol. 2017 Apr;221(2):73-80. doi: 10.1055/s-0043-102953. Epub 2017 May 23. German.

PMID:
28561211
22.

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD.

Breast Cancer Res Treat. 2017 Aug;164(3):737-743. doi: 10.1007/s10549-017-4296-3. Epub 2017 May 19.

PMID:
28526959
23.

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.

Body JJ, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, Mebis J, Peeters M, Pedrazzoli P, Caraceni A, Adamo V, Hechmati G.

Support Care Cancer. 2017 Sep;25(9):2823-2832. doi: 10.1007/s00520-017-3697-5. Epub 2017 Apr 21.

24.

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.

Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, Kimmig R, Kuhlmann JD.

Oncotarget. 2017 Jul 25;8(30):48820-48831. doi: 10.18632/oncotarget.16179.

25.

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.

Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2017 Apr 11;8(15):24303-24313. doi: 10.18632/oncotarget.13286.

26.

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.

Dewi DL, Mohapatra SR, Blanco Cabañes S, Adam I, Somarribas Patterson LF, Berdel B, Kahloon M, Thürmann L, Loth S, Heilmann K, Weichenhan D, Mücke O, Heiland I, Wimberger P, Kuhlmann JD, Kellner KH, Schott S, Plass C, Platten M, Gerhäuser C, Trump S, Opitz CA.

Oncoimmunology. 2017 Jan 3;6(2):e1274477. doi: 10.1080/2162402X.2016.1274477. eCollection 2017.

27.

Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study.

Meisel C, Sadowski CE, Kohlstedt D, Keller K, Stäritz F, Grübling N, Becker K, Mackenroth L, Rump A, Schröck E, Arnold N, Wimberger P, Kast K.

Arch Gynecol Obstet. 2017 May;295(5):1227-1238. doi: 10.1007/s00404-017-4330-z. Epub 2017 Mar 21.

PMID:
28324225
28.

Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J; Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO).

Gynecol Oncol Res Pract. 2017 Mar 7;4:6. doi: 10.1186/s40661-017-0040-2. eCollection 2017.

29.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663.

PMID:
27993805
30.

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study.

Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S.

Ann Surg Oncol. 2017 May;24(5):1314-1321. doi: 10.1245/s10434-016-5687-0. Epub 2016 Nov 28.

PMID:
27896515
31.

Photodynamic diagnosis with 5-aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study.

Hillemanns P, Wimberger P, Reif J, Stepp H, Klapdor R.

Lasers Surg Med. 2017 Feb;49(2):169-176. doi: 10.1002/lsm.22613. Epub 2016 Nov 16.

PMID:
27859395
32.

Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study.

Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann KH, Thiel FC, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S.

Eur J Cancer. 2016 Dec;69:180-188. doi: 10.1016/j.ejca.2016.09.038. Epub 2016 Nov 10.

PMID:
27837710
33.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
34.

Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.

Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A.

BMC Med Ethics. 2016 Oct 21;17(1):63.

35.

Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer.

Kast K, Dobberschütz C, Sadowski CE, Pistorius S, Wimberger P.

Arch Gynecol Obstet. 2016 Nov;294(6):1299-1303. Epub 2016 Aug 18.

PMID:
27535758
36.

Ready to clone: CNV detection and breakpoint fine-mapping in breast and ovarian cancer susceptibility genes by high-resolution array CGH.

Hackmann K, Kuhlee F, Betcheva-Krajcir E, Kahlert AK, Mackenroth L, Klink B, Di Donato N, Tzschach A, Kast K, Wimberger P, Schrock E, Rump A.

Breast Cancer Res Treat. 2016 Oct;159(3):585-90. doi: 10.1007/s10549-016-3956-z. Epub 2016 Aug 31.

PMID:
27581129
37.

Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.

Kuhlmann JD, Bankfalvi A, Schmid KW, Callies R, Kimmig R, Wimberger P, Siffert W, Bachmann HS.

BMC Cancer. 2016 Aug 9;16:618. doi: 10.1186/s12885-016-2662-x.

38.

Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.

Rump A, Benet-Pages A, Schubert S, Kuhlmann JD, Janavičius R, Macháčková E, Foretová L, Kleibl Z, Lhota F, Zemankova P, Betcheva-Krajcir E, Mackenroth L, Hackmann K, Lehmann J, Nissen A, DiDonato N, Opitz R, Thiele H, Kast K, Wimberger P, Holinski-Feder E, Emmert S, Schröck E, Klink B.

PLoS Genet. 2016 Aug 9;12(8):e1006248. doi: 10.1371/journal.pgen.1006248. eCollection 2016 Aug.

39.

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S.

Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27468640
40.

Implementation of Enhanced Recovery After Surgery (ERAS) Pathways in Gynecologic Oncology. A NOGGO-AGO* survey of 144 Gynecological Departments in Germany.

Muallem MZ, Dimitrova D, Pietzner K, Richter R, Feldheiser A, Scharfe I, Schmeil I, Hösl TM, Mustea A, Wimberger P, Burges A, Kimmig R, Sehouli J.

Anticancer Res. 2016 Aug;36(8):4227-32.

PMID:
27466536
41.

Avoiding OHSS: Controlled Ovarian Low-Dose Stimulation in Women with PCOS.

Fischer D, Reisenbüchler C, Rösner S, Haussmann J, Wimberger P, Goeckenjan M.

Geburtshilfe Frauenheilkd. 2016 Jun;76(6):718-726.

42.

Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

Blassl C, Kuhlmann JD, Webers A, Wimberger P, Fehm T, Neubauer H.

Mol Oncol. 2016 Aug;10(7):1030-42. doi: 10.1016/j.molonc.2016.04.002. Epub 2016 Apr 20.

43.

Erratum to: The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.

Arch Gynecol Obstet. 2016 Jun;293(6):1367. No abstract available.

PMID:
27075494
44.

Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?

Chebouti I, Blassl C, Wimberger P, Neubauer H, Fehm T, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2016 May 3;7(18):26454-64. doi: 10.18632/oncotarget.8524.

45.

Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.

Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Müller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J, Solomayer EF.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76. doi: 10.1007/s00432-016-2146-z. Epub 2016 Mar 23.

PMID:
27008006
46.

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.

Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C, Dikow N, Schott S, Rahner N, Niederacher D, Fehm T, Gehrig A, Mueller-Reible C, Arnold N, Maass N, Borck G, de Gregorio N, Scholz C, Auber B, Varon-Manteeva R, Speiser D, Horvath J, Lichey N, Wimberger P, Stark S, Faust U, Weber BH, Emons G, Zachariae S, Meindl A, Schmutzler RK, Engel C; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

J Med Genet. 2016 Jul;53(7):465-71. doi: 10.1136/jmedgenet-2015-103672. Epub 2016 Feb 29.

PMID:
26928436
47.

The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J.

Arch Gynecol Obstet. 2016 Apr;293(4):695-700. doi: 10.1007/s00404-016-4035-8. Epub 2016 Feb 19. Erratum in: Arch Gynecol Obstet. 2016 Jun;293(6):1367.

PMID:
26894303
48.

Prospects of adjuvant RANKL inhibition in breast cancer?

Rachner TD, Wimberger P, Hofbauer LC.

Cell Death Dis. 2015 Nov 19;6:e1982. doi: 10.1038/cddis.2015.332. No abstract available.

49.

Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J; Kommission Ovar of the AGO.

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1021-1027.

50.

Targeting Cancer Stem Cells: Promises and Challenges.

Kuhlmann JD, Hein L, Kurth I, Wimberger P, Dubrovska A.

Anticancer Agents Med Chem. 2016;16(1):38-58. Review.

PMID:
26179271

Supplemental Content

Loading ...
Support Center